Alligator Bioscience: Intensified business development efforts - SEB

Friday, February 14, 2020 6:38 AM
Following the Q4 report, we leave our estimates largely unchanged and reiterate our NPV based valuation range of SEK 17-21 per share. In 2020, we expect to see intensified efforts from Alligator to find a suitable partner for its products under clinical development and data for ATOR-1015.

After the loss of its big pharma partner, we argue that the risk is larger, but so is the potential
upside from entering a deal at a later stage.